SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the first clinical xenotransplant in its EXTEND study of the UThymoKidney™ in patients with ESRD. The transplant operation was performed at NYU Langone Health. The ongoing EXTEND study will evaluate the safety and efficacy of the UThymoKidney in ESRD patients who are not eligible for conventional allogeneic kidney transplantation or wh.








